Worthington Steel (WS) Enters Acquisition Agreement with Kloeckner & Co, Shares Surge 6.9%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy IBRX?
Source: Benzinga
- Acquisition Agreement: Worthington Steel Inc has entered into a Business Combination Agreement with Kloeckner & Co, planning a voluntary public offer to acquire all outstanding shares at €11 per share ($12.8), with management support and existing leadership expected to remain post-closing, thereby enhancing the company's market position and future growth potential.
- Stock Surge: Following the acquisition announcement, Worthington Steel's shares jumped 6.9% to $41.43, reflecting positive market expectations and increased investor confidence, which may provide financial support for the company's future developments.
- Industry Dynamics: On the same trading day, Kopin Corp shares rose 17.1% to $3.46, and ImmunityBio Inc shares increased by 17% to $4.62, indicating strong demand in the biotech and manufacturing sectors, potentially creating more investment opportunities for related companies.
- Positive Market Reaction: The overall market showed mixed performance, with the Nasdaq Composite gaining around 100 points, demonstrating continued investor interest and confidence in tech stocks, which may create a favorable market environment for Worthington Steel's acquisition plans.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.380
Low
5.00
Averages
7.33
High
9.00
Current: 7.380
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Global Expansion and Balance Sheet Strengthening
- Balance Sheet Strengthening: Founder Patrick Soon-Shiong indicated plans to strengthen the balance sheet and prepare for global expansion, despite recent stock price impacts from an FDA warning letter, the company is focused on achieving long-term growth.
- European Expansion Talks: Soon-Shiong mentioned discussions with a European health minister aimed at advancing 'immunotherapy 2.0', which will help the company promote NK cell and CD8 T-cell-based therapies in new markets, enhancing its competitive position.
- Declining Short Interest: Short interest in IBRX has decreased from 13.7% in mid-February to 12.9%, reflecting increased market confidence in the Anktiva therapy, especially after receiving conditional marketing authorization from the EU.
- FDA Warning Impact: Although the FDA issued a warning regarding Anktiva's promotional claims, leading to a short-term stock drop, the company is actively advancing clinical trials for new indications, demonstrating resilience and potential in the market.
See More
ImmunityBio Faces Class Action Over Misleading Claims
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026, and March 25, 2026, highlighting concerns over potential misleading actions by the company.
- FDA Warning Letter Exposed: The complaint alleges that CEO Soon-Shiong materially overstated Anktiva's capabilities, with a warning letter from the FDA on March 24, 2026, indicating that promotional communications misled the public by claiming Anktiva could cure and prevent all cancers.
- Significant Stock Drop: Following the FDA warning letter, ImmunityBio's stock fell by 21% on March 24, 2026, losing $1.98 per share and closing at $7.42, reflecting market concerns about the company's future prospects.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 26, 2026, indicating a growing emphasis on corporate governance and shareholder rights protection.
See More
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF's 52-week low is $66.66 per share, with a high of $132.09, and a recent trading price of $119.75, indicating stability within its volatility range that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on significant inflows (new units created) or outflows (old units destroyed), which will affect the underlying holdings of the ETF and influence market dynamics.
See More
Faruqi & Faruqi Investigates Potential Claims Against ImmunityBio
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, aiming to protect investor rights.
- Investor Contact Information: The firm encourages investors who suffered losses during the specified period to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Reminder: Faruq & Faruqi reminds investors that May 26, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against ImmunityBio, emphasizing the importance of timely action.
- Securities Law Expertise: As a leading national securities law firm, Faruq & Faruqi focuses on protecting investor rights and investigating potential securities fraud, demonstrating its expertise in maintaining market integrity.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, covering the period from January 19, 2026, to March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva medication, resulting in public statements that were materially misleading throughout the class period, potentially causing significant losses for investors.
- Investor Participation: Affected shareholders are encouraged to contact DJS Law Group to participate in the lawsuit, with the understanding that appointment as lead plaintiff is not required to partake in any recovery, thus providing an opportunity for investors to recover their losses.
- Law Group Expertise: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions, corporate governance litigation, and domestic/international M&A appraisals, committed to delivering high-value legal services to its clients.
See More
ImmunityBio's Bladder Cancer Drug Trial Confirms Statistical Power
- Trial Statistical Power Confirmed: The Independent Data Monitoring Committee (IDMC) confirmed that ImmunityBio's pivotal randomized trial for Anktiva is adequately powered with the current 366 participants, ensuring the study's effectiveness in detecting clinically meaningful differences in complete response rates.
- Clinical Trial Progress: The QUILT-2.005 trial evaluates Anktiva in combination with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer, showing promising results from earlier phases with prolonged complete remission durations, enhancing confidence for subsequent research.
- FDA Regulatory Dynamics: The U.S. FDA reviewed direct-to-consumer advertising for Anktiva, deeming it misleading and unsupported in claims of curing or preventing cancer, highlighting the importance of compliance in promotional materials.
- Analyst Ratings and Targets: ImmunityBio's stock carries a Buy rating with an average price target of $12.57, while D. Boral Capital maintains a target of $23.00, reflecting market confidence in the company's future potential.
See More
ImmunityBio's Global Expansion and Balance Sheet Strengthening
- Balance Sheet Strengthening: Founder Patrick Soon-Shiong indicated plans to strengthen the balance sheet and prepare for global expansion, despite recent stock price impacts from an FDA warning letter, the company is focused on achieving long-term growth.
- European Expansion Talks: Soon-Shiong mentioned discussions with a European health minister aimed at advancing 'immunotherapy 2.0', which will help the company promote NK cell and CD8 T-cell-based therapies in new markets, enhancing its competitive position.
- Declining Short Interest: Short interest in IBRX has decreased from 13.7% in mid-February to 12.9%, reflecting increased market confidence in the Anktiva therapy, especially after receiving conditional marketing authorization from the EU.
- FDA Warning Impact: Although the FDA issued a warning regarding Anktiva's promotional claims, leading to a short-term stock drop, the company is actively advancing clinical trials for new indications, demonstrating resilience and potential in the market.
See More
ImmunityBio Faces Class Action Over Misleading Claims
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026, and March 25, 2026, highlighting concerns over potential misleading actions by the company.
- FDA Warning Letter Exposed: The complaint alleges that CEO Soon-Shiong materially overstated Anktiva's capabilities, with a warning letter from the FDA on March 24, 2026, indicating that promotional communications misled the public by claiming Anktiva could cure and prevent all cancers.
- Significant Stock Drop: Following the FDA warning letter, ImmunityBio's stock fell by 21% on March 24, 2026, losing $1.98 per share and closing at $7.42, reflecting market concerns about the company's future prospects.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 26, 2026, indicating a growing emphasis on corporate governance and shareholder rights protection.
See More
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF's 52-week low is $66.66 per share, with a high of $132.09, and a recent trading price of $119.75, indicating stability within its volatility range that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on significant inflows (new units created) or outflows (old units destroyed), which will affect the underlying holdings of the ETF and influence market dynamics.
See More
Faruqi & Faruqi Investigates Potential Claims Against ImmunityBio
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, aiming to protect investor rights.
- Investor Contact Information: The firm encourages investors who suffered losses during the specified period to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Reminder: Faruq & Faruqi reminds investors that May 26, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against ImmunityBio, emphasizing the importance of timely action.
- Securities Law Expertise: As a leading national securities law firm, Faruq & Faruqi focuses on protecting investor rights and investigating potential securities fraud, demonstrating its expertise in maintaining market integrity.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, covering the period from January 19, 2026, to March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva medication, resulting in public statements that were materially misleading throughout the class period, potentially causing significant losses for investors.
- Investor Participation: Affected shareholders are encouraged to contact DJS Law Group to participate in the lawsuit, with the understanding that appointment as lead plaintiff is not required to partake in any recovery, thus providing an opportunity for investors to recover their losses.
- Law Group Expertise: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions, corporate governance litigation, and domestic/international M&A appraisals, committed to delivering high-value legal services to its clients.
See More
ImmunityBio's Bladder Cancer Drug Trial Confirms Statistical Power
- Trial Statistical Power Confirmed: The Independent Data Monitoring Committee (IDMC) confirmed that ImmunityBio's pivotal randomized trial for Anktiva is adequately powered with the current 366 participants, ensuring the study's effectiveness in detecting clinically meaningful differences in complete response rates.
- Clinical Trial Progress: The QUILT-2.005 trial evaluates Anktiva in combination with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer, showing promising results from earlier phases with prolonged complete remission durations, enhancing confidence for subsequent research.
- FDA Regulatory Dynamics: The U.S. FDA reviewed direct-to-consumer advertising for Anktiva, deeming it misleading and unsupported in claims of curing or preventing cancer, highlighting the importance of compliance in promotional materials.
- Analyst Ratings and Targets: ImmunityBio's stock carries a Buy rating with an average price target of $12.57, while D. Boral Capital maintains a target of $23.00, reflecting market confidence in the company's future potential.
See More
